Nerve growth factor signaling and Its contribution to pain von Barker, Philip A, Mantyh, Patrick, Arendt-Nielsen, Lars, Viktrup, Lars, Tive, Leslie

Volltext

Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety von Schmelz, Martin, Mantyh, Patrick, Malfait, Anne-Marie, Farrar, John, Yaksh, Tony, Tive, Leslie, Viktrup, Lars

Volltext

The Mechanism of Action of Phosphodiesterase Type 5 Inhibitors in the Treatment of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia von Giuliano, François, Ückert, Stefan, Maggi, Mario, Birder, Lori, Kissel, Jay, Viktrup, Lars

Volltext

Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized placebo- and tamsulosin-controlled 12-week study in Asian men von Yokoyama, Osamu, Yoshida, Masaki, Kim, Sae Chul, Wang, Chii-Jye, Imaoka, Takeshi, Morisaki, Yoji, Viktrup, Lars

Volltext

Long‐Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial von Hochberg, Marc C., Carrino, John A., Schnitzer, Thomas J., Guermazi, Ali, Walsh, David A., White, Alexander, Nakajo, Satoru, Fountaine, Robert J., Hickman, Anne, Pixton, Glenn, Viktrup, Lars, Brown, Mark T., West, Christine R., Verburg, Kenneth M.

Volltext

The not so hidden impact of interictal burden in migraine: A narrative review von Vincent, Maurice, Viktrup, Lars, Nicholson, Robert A., Ossipov, Michael H., Vargas, Bert B.

Volltext

Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety von Markman, John D., Bolash, Robert B., McAlindon, Timothy E., Kivitz, Alan J., Pombo-Suarez, Manuel, Ohtori, Seiji, Roemer, Frank W., Li, David J., Viktrup, Lars, Bramson, Candace, West, Christine R., Verburg, Kenneth M.

Volltext

Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis von Conaghan, Philip G, Abraham, Lucy, Viktrup, Lars, Cislo, Paul

Volltext

Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled... von Neogi, Tuhina, Hunter, David J, Churchill, Melvin, Shirinsky, Ivan, White, Alexander, Guermazi, Ali, Omata, Masanari, Fountaine, Robert J, Pixton, Glenn, Viktrup, Lars, Brown, Mark T, West, Christine R, Verburg, Kenneth M

Volltext

Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action von Andersson, Karl-Erik, de Groat, William C., McVary, Kevin T., Lue, Tom F., Maggi, Mario, Roehrborn, Claus G., Wyndaele, Jean Jacques, Melby, Thomas, Viktrup, Lars

Volltext

Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention von Lampl, Christian, Seng, Elizabeth, Vincent, Maurice, Lenderking, William R., Hoyt, Margaret, Hetherington, Lucinda, Ladd, Mary Kate, Malley, Karen, Chen, Jun, Viktrup, Lars

Volltext

Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction von Brock, Gerald, Broderick, Gregory, Roehrborn, Claus G., Xu, Lei, Wong, David, Viktrup, Lars

Volltext

Factors associated with physician-reported treatment status of patients with osteoarthritis pain von Schnitzer, Thomas J, Robinson, Rebecca L, Tive, Leslie, Cappelleri, Joseph C, Bushmakin, Andrew G, Jackson, James, Berry, Mia, Barlow, Sophie, Walker, Chloe, Viktrup, Lars

Volltext

Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to... von Viktrup, Lars, Hayes, Risa P, Wang, Ping, Shen, Wei

Volltext

The risk of lower urinary tract symptoms five years after the first delivery von Viktrup, Lars

Volltext

Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1‐year, open‐label extension study von Donatucci, Craig F., Brock, Gerald B., Goldfischer, Evan R., Pommerville, Peter J., Elion‐Mboussa, Albert, Kissel, Jay D., Viktrup, Lars

Volltext

Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Results from a randomized, double-blind, placebo-controlled... von Takeda, Masayuki, Yokoyama, Osamu, Lee, Sung Won, Murakami, Masahiro, Morisaki, Yoji, Viktrup, Lars

Volltext

Patients’ Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb) von Seng, Elizabeth, Lampl, Christian, Viktrup, Lars, Lenderking, William R., Karn, Hayley, Hoyt, Margaret, Kim, Gilwan, Ruff, Dustin, Ossipov, Michael H., Vincent, Maurice

Volltext

Efficacy and safety of tadalafil 5 mg once‐daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase ... von Zhang, Zhichao, Li, Hanzhong, Zhang, Xiaodong, Dai, Yutian, Park, Hyun Jun, Jiann, Bang‐Ping, Li, Peng, Lou, Ying, Ye, Zhangqun, Viktrup, Lars

Volltext

Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action von Yokoyama, Osamu, Igawa, Yasuhiko, Takeda, Masayuki, Yamaguchi, Takafumi, Murakami, Masahiro, Viktrup, Lars

Volltext